Results 181 to 190 of about 6,357 (207)

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

New England Journal of Medicine, 2007
Robert J Motzer, Thomas E Hutson, Stephane Oudard   +2 more
exaly  

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Lancet, The, 2008
Mario Santinami, Alessandro A E Testori, Reinhard Dummer   +2 more
exaly  

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

Journal of Clinical Oncology, 2001
Joseph G Ibrahim, Vernon K Sondak
exaly  

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Journal of Clinical Oncology, 2005
Vladimir Semiglazov, Tadeusz Pienkowski
exaly  

Physico-chemical properties and thermal stability of microcrystalline cellulose isolated from Alfa fibres

Carbohydrate Polymers, 2014
Djalal Trache, Kamel Khimeche, Nicolas Brosse   +2 more
exaly  

Epoetin-alfa/hydroxycarbamide/voxelotor

Reactions Weekly, 2022
openaire   +1 more source

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

New England Journal of Medicine, 2002
Michael W Fried, K Rajender Reddy, Dieter Häussinger   +2 more
exaly  

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial

Lancet, The, 2007
Simon Nadel, Mark John Peters
exaly  

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Journal of Clinical Oncology, 2009
Robert J Motzer, Thomas E Hutson, C?zary A Szczylik   +2 more
exaly  

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Lancet, The, 2023
exaly